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For the first time the incidence and mortality of breast cancer were estimated in French Guiana, an overseas French
Territory of South America. A certified cancer registry collected exhaustive data on breast cancer between 2003 and
2005. The age-standardized rate of breast cancer was 47.1 per 100 000 women. The age-standardized death rate
was 11.0 per 100 000 women. Although the standardized incidence and death rates were lower than in
metropolitan France and South America, the ratio between incidence and mortality showed that the prognosis of
breast cancer in French Guiana was worse than in metropolitan France (23 deaths per 100 incident cases versus 17
deaths per 100 incident cases, respectively). The demographics of French Guiana, suggests that mass organized
screening may benefit from lowering the age of its target population.
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Breast cancer is the most common type of cancer and the
most common cause of cancer-related death in women
worldwide (Parkin et al. 1999). Breast cancer is also a
major public health issue in South America. The incidence
is higher in temperate South American countries (69.14
per 100,000 women) than in tropical South American
countries (39.07 per 100,000 women) (Schwartsmann
2001). The incidence of breast cancer is higher in devel-
oped countries than in less developed countries
(Hortobagyi et al. 2005). On the contrary, mortality rates
are higher in less developed countries. French Guiana is a
French territory located on the Guiana shield. It attracts
numerous immigrants from South America and Caribbean
who migrate in search of better socioeconomic opportun-
ities. Thus, 30% of the population consists of immigrants
(INSEE 2011). The universal healthcare system is that of
France, and immigrants have access to health insurance,
although in practice this may be somewhat complicated.
Cases requiring specialized care are evacuated towards
metropolitan France or Martinique for treatment. Since
2005, French Guiana has set up a certified cancer registry.
The objective of the present paper is to report, for the first* Correspondence: tristan.roue@gmail.com
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in any medium, provided the original work is ptime, the incidence rate of breast cancer and its mortality
in this South American territory.Methods
The Cancer Registry of French Guiana was created in
2005 and is housed by the Regional Union of health care
professionals (URPS). It has been officially certified by
the Comité National des Registres (CNR) an emanation
of the INSERM (National Institute for Medical Research)
and the INVS (National Institute for Epidemiologic Sur-
veillance and Alert, French CDC) in 2010. Every three
years the registry undergoes a quality audit by the Comité
National des Registres. The objective of the registry is to
compile all patients living in French Guiana with malig-
nant invasive pathology and/or in situ lesions starting
January 1st 2003 in persons living in French Guiana, what-
ever the tumoral location and the place of diagnosis and
care. Benign tumours, recurrences and metastases, and
cancers of patients residing outside of French Guiana are
excluded. Cutaneous basocellular carcinoma and pituitary
gland tumours are excluded.
The registry is staffed by 3 trained research techni-
cians, a statistician, a secretary and two medical doctors.
It has a scientific board and an ethical review board.
The database has national approval by the Comission
Nationale Informatique et Libertés (CNIL). All confiden-
tial information, within the Registry is encoded, protectedOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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No published results can enable the identification of indi-
viduals (Roue et al. 2012).
Cancer cases must be confirmed on at least 2 sources.
Between 2003 and 2006 one breast cancer case was not
included since it was not confirmed by a second source.
The search for the cases is active. The three main
sources are pathologists, medical information offices of
public and private hospitals and health insurance notifica-
tions. After first notification of cases, every medical file is
checked in different laboratories, private and public hos-
pital departments, administrative services and medical
specialists in French Guiana and outside the registration
area. Arrangements have been made with the hospitals
outside the registration area to notify the registry of any
resident cancer cases that they diagnose and treat. The
capture-recapture method was used to estimate the com-
pleteness of cancer registration. The principle of the
capture-recapture method is that by comparing cases in
three overlapping data sources, the number of unascer-
tained cases can be estimated. The validity of the estimate
relies on 3 basic assumptions: cases must be accurately
matched, study population is closed and the individuals
have equal catchability. To take into account all possible
two-way interactions (dependencies) between the data
sources and correct for these, log-linear models were fitted
to the observed cases producing a maximum likelihood
estimate for unascertained cases. The model fit can be
evaluated by comparing p-values and/or the Akaikes
Information Criterion (AIC) (an der Heiden 2009). The
model with the two interaction terms between patholo-
gists and medical information offices of public and private
hospitals and between pathologists and health insurance
notifications, was selected as the best fitting (AIC = −1.93)
model. According to this model, 4 cases of breast cancer
were missed between 2003 and 2006: completeness was
estimated to be 97%. Retrospective data regarding the pa-
tient identity, demographics, diagnosis, date of diagnosis,
stage of disease, the nature, the place and the date ofFigure 1 Incidence and mortality per 100,000 women by age group itreatment are recorded. The vital status of patients is
checked regularly. The follow-up for the vital status is im-
portant to evaluate survival after diagnosis and treatment,
and it can be done actively through the RNIPP (Repertoire
National d’Identification des Personnes Physiques) an em-
anation of the Insee (Institut national de la statistique et
des études économiques), or passively by matching death
certificates in the town council. Because patients often
need medical transfer to metropolitan France or
Martinique, 208 sources were consulted to collect the re-
quired data for breast cancer and the average number of
sources per registered case is over six. Duplicate observa-
tions are removed. Data coding strictly follows procedures
of the FRANCIM (Réseau Français des Registres de Can-
cer) & ENCR (European Network of Cancer Registries)
network. Tumour topography and morphology are coded
according to the international classification of diseases for
oncology (ICM-O-3). The TNM stage is coded according
to the International Union against Cancer (edition of the
studied years).
Data is entered on MOViBASE and was analysed using
STATA 11®. The total number of cancer cases was
reported, a crude incidence rate was calculated with
population of French Guiana as a reference. Comparability
of incidence rates is ensured by using age-standardized
rates using the world population as a reference (direct
standardization). Mortality data was obtained through the
INSERM database (CépiDC) which compiles data from
death certificates throughout France.
Results
The median age at diagnosis was 50 years (interquartile
range: 44–59 years), the youngest patient was 27 years
old and the oldest was 92 years old. Between 2003 and
2006, there were 147 new cases of breast cancer, which
corresponded to a crude incidence rate of 36.7 per
100,000 women (95% confidence interval [CI], 30.8–42.6).
The standardized incidence rate was 47.1 per 100,000
women (95% CI, 39.0–55.2). Overall breast cancern French Guiana between 2003 and 2006.
Figure 2 Incidence rate and mortality rate of breast cancer.
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breast cancer grew significantly after 40 years of age and
peaked at 211.2 per 100,000 women between 45 and
54 years and then decreases after 55 years of age
(Figure 1).
The median age at death from breast cancer was
52 years (interquartile range: 46–64 years), the youngest
patient was 28 years old and the oldest was 85 years old.
In French Guiana, breast cancer is the first case of cancer
related death in women and the 4th cause of cancer-
related death in the global population. The crude mortality
rate by breast cancer was 8.0 per 100,000 women (95% CI,
5.2–10.8). The standardized mortality rate was 11.0 deaths
per 100,000 women (95% CI, 7.0–15.1).
Histoprognostic grading according to Scarff Bloom
and Richardson’s classification (SBR) showed that 12% were
SBRI (good prognosis), 44% were SBRII (intermediateFigure 3 Comparison of stage at diagnosis of breast cancer betweenprognosis), and 34% were SBRIII (unfavourable prognosis).
For 10% the data was unavailable.
The staging was assigned to 1 of 5 categories: the
staging at the time of diagnosis showed that 20% of
T1N0M0 (tumour ≤ 2 cm, node-negative), 20% of T2–
3N0M0 (tumour ≥ 2 cm and ≤ 5 cm, node-negative),
39% of T1–3 N +M0 (tumour > 5 cm, node-positive,
regardless of the number and anatomic level of the in-
volved nodes in the axilla), 5% of T4N×M0 (any size
with extension to the skin or the thorax wall, regardless
of nodal status), 9% of M1 (metastatic and unspecified
stage). Between 2003 and 2006, 8% of breast cancer
cases were in situ lesions.
Over 96% of women benefited from treatment within
8 weeks, among which 64% outside of French Guiana.
Within 4 months following the diagnosis, surgery
concerned 76% of treated patients (among whom 73%French Guiana, Europe and four French cancer registries.
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whom 78% outside of French Guiana), radiotherapy for
8% (always outside of French Guiana), and hormone
therapy for 9% (among whom 70% outside of French
Guiana). Eighty four percent of surgical interventions
were considered to be curative, the limits of the surgery
were free of any remaining tumour.
Discussion
In French Guiana, the incidence of breast cancer is on
par with the overall incidence in South America, but
slightly higher than the incidence in tropical South
America (Schwartsmann 2001). In contrast the standard-
ized incidence of breast cancer in this French overseas
territory is markedly lower than in metropolitan France
(Belot et al. 2009). The standardized death rate was
lower in French Guiana than in South America and
metropolitan France (Belot et al. 2009). However, the
ratio between mortality and incidence of breast cancer
may indirectly reflect the influence of early diagnosis.
Here the ratio is higher than in metropolitan France, but
lower than South America (Figure 2). Thus the prognosis
of breast cancer in French Guiana is worse than in France
with 23 deaths per 100 incident cases against 17 per 100
in metropolitan France. This excess may be explained by a
later diagnosis. At the time of diagnosis 39% of women
had T1–3 N +M0 (tumour > 5 cm, node-positive) and 9%
had a metastatic stage. Figure 3 shows that, in this
ultraperipheric region of Europe, there is a statistically
significant diagnostic delay compared to earlier data from
mainland Europe and France (Sant et al. 2003).
Since 2004, mass organized screening was initiated
throughout the French territory. All women aged 50–
74 years are concerned by this every 2 years. In French
Guiana, this strategy was initiated in 2005 by the Guianese
Association for Organized Cancer Screening (AGDOC).
Because of the young age of the population in French
Guiana, the median age of women at the time of diagnosis
is 50 years against 61 in metropolitan France. Fifty percent
of breast cancer cases are diagnosed among women
aged <50 years old whereas this figure is 21% in metropol-
itan France. This suggests that lowering the age of women
targeted by organized screening may be warranted given
the local epidemiology.
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